文献速递临床试验与 GCP

血管内超声肾去神经术治疗高血压:RADIANCE II随机临床试验

Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

RADIANCE II是一项假手术对照随机临床试验,在美国37个中心和欧洲24个中心开展,纳入150例超声肾去神经术患者和74例假手术患者。结果显示,2个月时日间动态收缩压降幅在超声肾去神经术组为-7.9 mmHg,假手术组为-1.8 mmHg,基线校正组间差异为-6.3 mmHg(95%CI,-9.3至-3.2 mmHg,P<.001),且两组均未报告主要不良事件。

要点

  • 超声肾去神经术组2个月日间动态收缩压降幅大于假手术组,基线校正组间差异为-6.3 mmHg。
  • 7项次要血压结局中6项在超声肾去神经术组显著改善。
  • 两组均未报告主要不良事件。

核心结论

  • 在高血压患者中,与假手术相比,超声肾去神经术在未使用降压药物的情况下降低了2个月时的日间动态收缩压,且术后未发生主要不良事件。

研究设计与样本

  • 假手术对照、随机临床试验,患者和结局评估者对治疗分组设盲,于2019年1月14日至2022年3月25日在美国37个中心和欧洲24个中心开展,按中心分层随机。
  • 纳入18至75岁高血压患者(诊室坐位收缩压≥140 mmHg且舒张压≥90 mmHg,尽管服用最多2种降压药物),在停药4周后动态收缩压/舒张压≥135/85 mmHg且<170/105 mmHg,估算肾小球滤过率≥40 mL/min/1.73 m2且肾动脉解剖合适。
  • 共1038例合格患者,150例随机至超声肾去神经术,74例随机至假手术(平均年龄55岁[SD,9.3岁];女性28.6%;自认为黑人或非裔美国人16.1%)。

主要发现

  • 日间动态收缩压降幅在超声肾去神经术组(均值-7.9 mmHg[SD,11.6 mmHg])大于假手术组(均值-1.8 mmHg[SD,9.5 mmHg]),基线校正组间差异为-6.3 mmHg(95%CI,-9.3至-3.2 mmHg),P<.001。
  • 超声肾去神经术的效应在整个24小时昼夜周期中一致。
  • 7项次要血压结局中6项在超声肾去神经术组较假手术组显著改善。
  • 两组均未报告主要不良事件。

关键数值与推荐

  • 主要疗效结局为2个月时日间动态收缩压的平均变化。
  • 主要安全复合结局为主要不良事件,包括30天时的死亡、肾衰竭以及主要栓塞、血管、心血管、脑血管和高血压事件,以及6个月时检测到的肾动脉狭窄大于70%。
  • 次要结局包括2个月时24小时动态收缩压、家庭收缩压、诊室收缩压和所有舒张压参数的平均变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Two initial sham-controlled trials demonstrated that ultrasound renal denervation decreases blood pressure (BP) in patients with mild to moderate hypertension and hypertension that is resistant to treatment. OBJECTIVE: To study the efficacy and safety of ultrasound renal denervation without the confounding influence of antihypertensive medications in patients with hypertension. DESIGN, SETTING, AND PARTICIPANTS: Sham-controlled, randomized clinical trial with patients and outcome assessors blinded to treatment assignment that was conducted between January 14, 2019, and March 25, 2022, at 37 centers in the US and 24 centers in Europe, with randomization stratified by center. Patients aged 18 years to 75 years with hypertension (seated office systolic BP [SBP] ≥140 mm Hg and diastolic BP [DBP] ≥90 mm Hg despite taking up to 2 antihypertensive medications) were eligible if they had an ambulatory SBP/DBP of 135/85 mm Hg or greater and an SBP/DBP less than 170/105 mm Hg after a 4-week washout of their medications. Patients with an estimated glomerular filtration rate of 40 mL/min/1.73 m2 or greater and with suitable renal artery anatomy were randomized 2:1 to undergo ultrasound renal denervation or a sham procedure. Patients were to abstain from antihypertensive medications until the 2-month follow-up unless prespecified BP criteria were exceeded and were associated with clinical symptoms. INTERVENTIONS: Ultrasound renal denervation vs a sham procedure. MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was the mean change in daytime ambulatory SBP at 2 months. The primary safety composite outcome of major adverse events included death, kidney failure, and major embolic, vascular, cardiovascular, cerebrovascular, and hypertensive events at 30 days and renal artery stenosis greater than 70% detected at 6 months. The secondary outcomes included mean change in 24-hour ambulatory SBP, home SBP, office SBP, and all DBP parameters at 2 months. RESULTS: Among 1038 eligible patients, 150 were randomized to ultrasound renal denervation and 74 to a sham procedure (mean age, 55 years [SD, 9.3 years]; 28.6% female; and 16.1% self-identified as Black or African American). The reduction in daytime ambulatory SBP was greater with ultrasound renal denervation (mean, -7.9 mm Hg [SD, 11.6 mm Hg]) vs the sham procedure (mean, -1.8 mm Hg [SD, 9.5 mm Hg]) (baseline-adjusted between-group difference, -6.3 mm Hg [95% CI, -9.3 to -3.2 mm Hg], P < .001), with a consistent effect of ultrasound renal denervation throughout the 24-hour circadian cycle. Among 7 secondary BP outcomes, 6 were significantly improved with ultrasound renal denervation vs the sham procedure. No major adverse events were reported in either group. CONCLUSIONS AND RELEVANCE: In patients with hypertension, ultrasound renal denervation reduced daytime ambulatory SBP at 2 months in the absence of antihypertensive medications vs a sham procedure without postprocedural major adverse events. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03614260.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Azizi M, Saxena M, Wang Y, et al. Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial. JAMA. 2023. PMID: 36853250. doi:10.1001/jama.2023.0713

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。